Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.55 |
| ▸ | F2 | P00734 | 3/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PROC | P04070 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6857468 | 0.92 | F10 (0.51) | F10F2PRSS1NPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL6553711 | 0.91 | F10 (0.44) | F10F2NPC1RAB9AHRH3 | |
| Trifluoroacetic Acid SCHEMBL6553736 | 0.86 | F10 (0.39) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL7568684 | 0.81 | F10 (0.80) | F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL6553710 | 0.81 | F10 (0.61) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL3905673 | 0.76 | F10 (0.92) | F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL3902136 | 0.76 | F10 (0.74) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL6553831 | 0.76 | F10 (0.38) | F10F2NPC1RAB9AHRH3 | |
| SCHEMBL6555792 | 0.75 | F10 (0.62) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL6857478 | 0.73 | F10 (0.59) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784191-B2 | AS BLOOD-COAGULATION INHIBITOR OR AN AGENT FOR THERAPY AND PROPHYLAXIS OF THROMBOSIS OR EMBOLISM, CONTAINING | AJINOMOTO CO., INC. (JP) | 2004-08-31 | — | — | US | disclosed |
| EP-1236735-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20020193348-A1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1236735-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193348-A1 | Benzamidine derivatives | SERPINC1, SERPINE1, TFPI | F10 14/4885F2 4/4885PRSS1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.